UC Davis Health Specialty Pharmacy one of few to provide mavacamten
(SACRAMENTO)
The UC Davis Specialty Pharmacy is excited to announce it is now one of the few West Coast health system specialty pharmacies with access to mavacamten, a breakthrough drug for symptomatic obstructive hypertrophic cardiomyopathy (HoCM).
The treatment is available exclusively through the Risk Evaluation and Mitigation Strategy (REMS) program, an initiative designed to ensure that the medication's benefits outweigh any potential risks.
Members of the Specialty Pharmacy team.
Through patient education, thorough screening for drug-to-drug interactions, and seamless coordination, UC Davis Health cardiology pharmacists and technicians ensure timely and safe delivery of this critical medication, which is vital for improving patient outcomes in the management of HoCM.
This milestone highlights UC Davis Health's commitment to providing specialized care and cutting-edge treatments while further strengthening our expertise in supporting rare disease management. With access to mavacamten, we can better serve our patients, ensuring they receive top-tier care and support.
As a trusted provider of limited distribution medications, we remain dedicated to expanding access to transformative treatments.
